Duori Pharmaceuticals announced that on January 21, 2026, Wang Qingtai and Cao Xiaobing delivered the “Tibet Duori Pharmaceuticals Co., Ltd. Tender Offer Report,” with an offer price of 32.07 yuan per share and a total of 19.44 million shares tendered, accounting for 24.30% of the company’s total share capital. As of February 24, 2026, the tender offer period has expired. The company’s stock will be suspended from trading starting at the market open on February 25, 2026 (Wednesday), and will resume trading on the market open on the day the tender offer results are announced.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Duori Pharmaceuticals: The tender offer period has expired; the stock will be suspended from trading starting February 25, 2026.
Duori Pharmaceuticals announced that on January 21, 2026, Wang Qingtai and Cao Xiaobing delivered the “Tibet Duori Pharmaceuticals Co., Ltd. Tender Offer Report,” with an offer price of 32.07 yuan per share and a total of 19.44 million shares tendered, accounting for 24.30% of the company’s total share capital. As of February 24, 2026, the tender offer period has expired. The company’s stock will be suspended from trading starting at the market open on February 25, 2026 (Wednesday), and will resume trading on the market open on the day the tender offer results are announced.